|
- Aliada Therapeutics is now part of AbbVie
Aliada Therapeutics is now part of AbbVie We discover and develop innovative medicines for tomorrow, while helping people live better lives today Read the announcement
- AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in . . .
Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL™) platform, engineered for high-precision CNS drug delivery The novel BBB-crossing technology targets transferrin and CD98 receptors (TfR and CD98) which are highly expressed in brain endothelial cells
- ALIADA RESTAURANT | Greek and Cypriot Cuisine
Est 2002 2919 Broadway, Astoria, NY 11106 Phone: (718) 932-2240 VIEW OUR MENUS MAKE A RESERVATION
- AbbVie inks $1. 4B Aliada buyout, landing ex-J J Alzheimers . . .
The acquisition will give AbbVie control of an Alzheimer’s disease drug candidate Aliada in-licensed from Johnson Johnson to try to improve on the first generation of anti-amyloid-beta
- AbbVie to acquire a J J-backed brain drugmaker for $1. 4B
The deal, announced Monday, is expected to close by the end of the year, and has AbbVie buying all the outstanding shares of Aliada Therapeutics for $1 4 billion in cash A private company, Aliada formed in 2021 with seed funding from J J’s venture arm and the investment firm RA Capital Management
- AbbVie gets bigger in Alzheimers R D with Aliada takeover
AbbVie has boosted its Alzheimer's disease pipeline with a $1 4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing
- AbbVie to Acquire Aliada Therapeutics for $1. 4 Billion - WSJ
The biopharmaceutical company agreed to buy Aliada in a deal that adds a potential therapy for Alzheimer’s disease to AbbVie’s neuroscience pipeline
|
|
|